• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

European, Asian pharma stocks rally as Trump spares sector from reciprocal tariffs but the cheer may be shortlived

by April 3, 2025
by April 3, 2025

Pharmaceutical stocks saw strong gains on Thursday after US President Donald Trump announced that pharmaceuticals would be exempt from the latest round of reciprocal tariffs on global imports.

The exemption has provided a much-needed boost to the sector, particularly for Indian and European drugmakers, which rely heavily on US sales.

However, analysts have cautioned that broader tariff risks still loom over the industry.

European pharma stocks climb, but uncertainty remains

Following Trump’s announcement, major pharmaceutical stocks across Europe and Asia posted gains.

In the UK, AstraZeneca and GlaxoSmithKline (GSK) both climbed about 1.5%, while Swiss drugmaker Novartis gained 0.69%.

France’s Sanofi also edged higher by 0.3%.

However, Swiss pharmaceutical giant Roche fell 2.3% after its multiple sclerosis drug Ocrevus failed to meet its primary endpoint in a key clinical trial.

While the immediate exemption of pharmaceuticals has been welcomed by the industry, analysts warn that uncertainties remain.

Shore Capital healthcare analyst Sean Conroy noted that a White House fact sheet indicated pharmaceuticals were excluded from the new tariff measures.

However, he added, “It is still somewhat unclear whether the broader-reaching 10% baseline tariffs could still be levied against imported drugs and vaccines.”

Similarly, analysts at Bryan Garnier Research pointed out that Trump’s mixed messaging left room for potential future tariff risks.

The US president had remarked that drugmakers “will come roaring back to the US, because if they don’t, they got a big tax to pay.”

Asian, Indian healthcare stocks rally

Asian healthcare stocks also rallied, led by Indian generic drugmakers, even as the broader market declined.

The CNX Pharma index, which tracks Indian pharmaceutical companies, surged more than 3%, marking its biggest one-day gain in 10 months.

In contrast, India’s benchmark Nifty 50 index fell 0.25% on the day.

Sun Pharma, Cipla, and Dr. Reddy’s Laboratories, the country’s three largest drugmakers by revenue, gained between 3% and 6%.

India, one of the largest suppliers of generic medicines to the US, stands to benefit the most from the exemption.

The US accounted for nearly a third, or $9 billion, of India’s total pharmaceutical exports last fiscal year, with most of these being low-cost generic drugs.

Japan’s pharmaceutical sector also benefited, with Takeda Pharmaceuticals and Daiichi Sankyo advancing 2% and 2.7%, respectively.

However, Japan’s broader Nikkei 225 index tumbled to an eight-month low, reflecting investor concerns over the wider impact of US tariffs on global trade.

Japan’s exports to the US were also substantial, amounting to $6.34 billion in 2023, according to data from research firm OEC.

Jefferies analysts noted that while Indian drugmakers “can breathe easy for now,” the risk of future tariffs remains.

“Higher tariffs at a later date cannot be ruled out, but for now, this exemption allows Indian firms to maintain their competitive edge in the US market,” Jefferies said in a note.

What to expect in the coming days?

Looking ahead, analysts suggest that pharmaceutical companies will closely monitor the Trump administration’s stance on trade policies.

Bloomberg has reported that the US government is considering launching a Section 232 investigation into pharmaceuticals, semiconductors, and critical minerals, similar to previous probes that resulted in tariffs on cars and aluminium.

BNP Paribas India analyst Tausif Shaikh stated, “Assuming a 10% tariff is imposed on pharma products, we expect the impact to be negligible. However, with the sector exempted from reciprocal tariffs currently, we expect a relief rally for the Nifty Pharma Index, after its 11% year-to-date decline.”

While the immediate outlook for pharmaceutical stocks appears positive, the industry remains vulnerable to policy shifts in the ongoing US trade war.

Investors and drugmakers alike will be watching closely for any further developments from Washington.

The post European, Asian pharma stocks rally as Trump spares sector from reciprocal tariffs but the cheer may be shortlived appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Short US30: bearish momentum strengthens as trade war fears and technical breakdown signal further downside risk
next post
Is it a golden opportunity to buy the Nasdaq 100 index crash?

Related Posts

Opendoor stock plunges 21% after weak forecast: could...

August 7, 2025

Why Upstart stock tanked on Q2 earnings and...

August 7, 2025

GLD ETF analysis: is this gold fund on...

August 7, 2025

Asian markets open: Nikkei flat on US chip...

August 7, 2025

Europe markets open: Stocks rise; Maersk Q2 profit...

August 7, 2025

SoftBank posts strong quarterly profit of around $2.9B...

August 7, 2025

Trump and Putin to meet next week; White...

August 7, 2025

Is America really getting rich off tariff revenue?

August 7, 2025

Israel’s Leviathan gas field secures historic $35B export...

August 7, 2025

Trump’s tariff gamble on chips and drugs could...

August 6, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • What Families Gain at the Dinner Table

    August 7, 2025
  • Superman, Sneaking Snacks into Movies, and the Mystery of Social Order

    August 7, 2025
  • How Telematics Is Reshaping Transportation

    August 7, 2025
  • What Families Gain at the Dinner Table

    August 7, 2025
  • Would Superman Bring Coffee to the Movies?

    August 7, 2025
  • Opendoor stock plunges 21% after weak forecast: could more downside be ahead?

    August 7, 2025

Editors’ Picks

  • 1

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 2

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 5

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025
  • 6

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025
  • 7

    Elon Musk says federal employees must fill out productivity reports or resign

    February 23, 2025

Categories

  • Economy (2,114)
  • Editor's Pick (210)
  • Investing (185)
  • Stock (1,413)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

S&P 500 slips as economic uncertainty weighs...

March 21, 2025

Asian stocks were broadly higher: Hang Seng...

July 21, 2025

EU-US trade deal: 15% tariff, $750B energy...

July 28, 2025